Attached files

file filename
10-K - FORM 10-K - Molecular Templates, Inc.d269230d10k.htm
EX-23.1 - CONSENT OF ERNST & YOUNG LLP - Molecular Templates, Inc.d269230dex231.htm
EX-10.2 - 2004 AMENDED AND RESTATED EQUITY INCENTIVE PLAN (AS AMENDED ON MAY 19, 2010) - Molecular Templates, Inc.d269230dex102.htm
EX-31.1 - CERTIFICATION PURSUANT TO RULE 15D-14 OF THE SECURITIES AND EXCHANGE ACT OF 1934 - Molecular Templates, Inc.d269230dex311.htm
EX-32.1 - CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 - Molecular Templates, Inc.d269230dex321.htm
EX-31.2 - CERTIFICATION PURSUANT TO RULE 15D-14 OF THE SECURITIES AND EXCHANGE ACT OF 1934 - Molecular Templates, Inc.d269230dex312.htm
EXCEL - IDEA: XBRL DOCUMENT - Molecular Templates, Inc.Financial_Report.xls
EX-23.2 - CONSENT OF PRICEWATERHOUSECOOPERS LLP - Molecular Templates, Inc.d269230dex232.htm

Exhibit 32.2

Threshold Pharmaceuticals, Inc

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Threshold Pharmaceuticals, Inc (the “Company”) on Form 10-K for the year ended December 31, 2011, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Joel A. Fernandes, Vice President, Finance and Controller of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 15, 2012

 

/s/    Joel A. Fernandes

Joel A. Fernandes

Vice President, Finance and Controller

(Principal Accounting Officer)